
|Articles|July 15, 2004
Toric IOL outperforms comparable spherical lens in FDA trial
San Diego - The AcrySof Toric IOL (Alcon Laboratories, Fort Worth, TX) is outperforming a comparable spherical IOL in uncorrected visual acuity (UCVA) levels and the low level of residual astigmatism. The interim safety and efficacy results of the FDA clinical trial of the AcrySof Toric IOL were presented here at the annual meeting of the American Society of Cataract and Refractive Surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Beyond the surface: Tackling complex dry eye cases
3
Redefining glaucoma care: Where innovation meets clinical insight
4
An Extreme Case of Demodex Blepharitis: From Misdiagnosis to Remarkable Recovery
5



















































.png)


